← Back

Wire · regulatory

US FDA proposes to withdraw approval for Salerno's cholesterol medication

Published

18 November 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

The US FDA is proposing to withdraw approval for Salerno Pharmaceuticals' cholesterol medication FloLipid due to repeated failure to file required annual reports, with the company given a chance for a hearing to contest this.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

Regulatory non-compliance by Salerno opens a door for competitors to fill the liquid cholesterol medication gap. You need to watch for similar approval risks that could disrupt supplier stability in your sector.

◆ Coverage

3 sources · 18 Nov 2026

◆ Related on Wire

◆ Topics

MedtechFDAdrug-approvalcholesterol-medicationregulatory-complianceSalerno